Download Thursday, June 2, 2016

Программа конференции
LIST OF POSTERS
Please note that each poster will be on display for one day only. There will be two groups of
posters – the first one will be displayed on Thursday, June 2 and the second one on Friday, June 3
(see below).
Poster instructions available here.
Thursday, June 2, 2016
“From everyday clinical practice”
P-001
Myocardial revascularization in the elderly patients
E. Grichuk (Russia)
P-002
Lipid profile in adolescents with focus on family history
G. Grujić Ilić (Serbia)
P-003
Matching of order rank over time measurements of blood pressure fluctuation and pulse
wave velocity of the day using a wristwatch-type blood pressure meter in hemiplegics of the
maintenance phase
A. Kimura (Japan)
P-004
Personalized approach to evaluate of the long-term prognosis of acute coronary syndrome
with persistent ST-segment elevation
N. Lozhkina (Russia)
P-005
Coronary stenting results in elderly patients with acute cocronary syndrome
L. Sodnomova (Russia)
P-006
EECP
T. Tak (United States)
P-007
Cognitive deficits, dyslipidemia and patterns of statin therapy in patients with nonhemorrhagic stroke
M. Vorobyeva (Russia)
Anticoagulant Therapy (NOAC)
P-008
Prevention of thromboembolic disease in elderly hospitalized patients
J. Lopez-Picazo (Spain)
Cardiology/Hypertension
P-009
LDL and HDL subclases in relation to intima media thickness in coronary artery disease
S. Alabakovska (Macedonia)
P-010
Atherosclerosis and arteriosclerosis in men with prehypertension
O. Antropova (Russia)
P-011
Use of statin in ischemic heart failure
D. Arnopolskaya (Uzbekistan)
P-012
Indicators of ambulatory blood pressure monitoring in patients with neurocirculatory
dystonia
O. Babenko (Ukraine)
P-013
Comparative evaluation of clinical data in patients with myocardial bridge and atherosclerotic
stenosis of coronary arteries
Z. Bagmanova (Russia)
P-014
The influence of biosynthesis of interleukin-6 on the change of the production of interleukin1ß in blood serum at patients with Q-wave myocardial infarction complicated by acute heart
failure
K. Belokoneva (Russia)
P-015
Coronary artery disease in women in Morocco
M. Benomar (Morocco)
P-018
Risk of resistant hypertension: Role of arterial stiffness and baroreflex disfunction
I. Emelyanov (Russia)
P-019
Relationship of the heart rate in the heart prenosological changes in young adults
E. Esina (Russia)
P-020
Effect of lipid-lowering therapy on coronary plaque composition in diabetic patients
assessed by virtual histology intravascular ultrasound
B.-K. Hong (Korea)
P-021
Diagnosis of decompression intravascular gas formation in divers, the method of
radionuclide scintigraphy of the myocardium
D. Cherkashin (Russia)
P-022
The role of adipokines in obesity-related hypertension
I. Iuliia (Russia)
P-023
Sex differences in the effects of high-fat diet feeding on rat heart Na+/K+-ATPase activity
A. Jovanovic (Serbia)
P-024
Matching rate of rank the between the pulse wave velocity and wearable wristwatch-type
sphygmomanometer in 24 hours of hemiplegia in the maintenance phase for health care
A. Kimura (Japan)
P-025
Associations of psycho-social risk factors and the severity of coronary bed lesion with lipid
parameters in patients with acute coronary syndrome who live in the North
K. Kozhokar (Russia)
P-026
The prevalence of asymptomatic organ damage in patients with hypertension
E. Kramarenko (Russia)
P-027
Proinflammatory cytokines serum levels and clinical course of acute myocardial infarction
O. Soldatova (Russia)
P-029
Coronary atherosclerosis and red blood cell dysfunction: systematic approach for real
clinical practice implementation
L. Malinova (Russia)
P-030
Features of left ventricular remodeling in patients with arterial hypertension and multifocal
coronary arteries defeat
A. Malov (Russia)
P-031
Impact of losartan on indicators of exercise tolerance and quality of life in patients with
chronic heart failure
D. Masharipova (Uzbekistan)
P-032
An elevation serum level of endothelial monocyte activating polypeptide-II in hypertensive
patients with type 2 diabetes and obesity
L. Mogylnytska (Ukraine)
P-033
Changes in the Structure and Function of Myocardium in Geriatric Patients with Coronary
Atherosclerosis Who were Referred for Percutaneous Coronary Intervention
I. Nikishchenkova (Russia)
P-034
Genetic determinism of family forms of thrombophilia in patients with coronary heart disease
E. Nomokonova (Russia)
P-036
Angiotensin II -induced rat VSMC proliferation involves ADAM12 and PKCδ via EGFR –
dependent and –independent signaling pathways
M. Obradovic (Serbia)
P-037
Carotid plaque instability in patients with acute coronary syndrome estimated with high
resolution ultrasound
M. Tripoten (Russia)
P-038
Arterial stiffness in patients with ischemic stroke and arterial hypertension
M. Bezzubtseva (Russia)
P-039
Is genesis ventricular arrhythmias in patients with stable coronary artery disease always
obvious?
E. Ryngach (Russia)
P-040
Coronary vessels atherosclerosis in hypertension patients
O. Smolenskaya (Russia)
P-042
Pre-hypertension and arterial hypertension in women with the early stage of rheumatoid
arthritis
J. Starodubova (Russia)
P-043
Risk factors and prognosis of acute myocardial infarction in patients of middle age
I. Suspitsyna (Russia)
P-044
Subclinical carotid atherosclerosis in female rheumatoid arthritis patients
E. Tsareva (Russia)
P-045
Comparative efficacy of antihypertensive drugs in patients with metabolic syndrome
J. Uzokov (Uzbekistan)
P-046
The study on carotid atherosclerosis associated to certain biochemical blood parameters
T. Vachmistrova (Russia)
P-047
Loading doses of statins before elective percutaneous coronary interventions
E. Vershinina (Russia)
P-048
Predictors of attainment target lipid levels in high cardiovascular risk patients
M. Vorobyeva (Russia)
P-049
Carbon monoxide releasing molecule induces endothelial nitric oxide synthase activation by
calcium and PI3/Akt-dependent mechanism
B.-S. Wung (Taiwan)
P-050
Elevated Lipoprotein(a) is associated with Worse Prognosis in Diabetic Patients with
symptomatic Coronary Artery Disease
Y.-W. Yoon (Korea)
P-051
Lipoprotein subclasses and activities of LCAT and CETP in hypertensive obese children
A. Zeljkovic (Serbia)
P-052
The features of the gene expression of the monocytes scavenger receptor in different clinical
forms of atherosclerosis Davlyatshina NZ, Mayanskaya SD, Grishina EA, Kravtsova, OA
Kazan State Medical University, Kazan, Russia Kazan Federal University, Kazan, Russia
S. Mayanskaya (Russia)
Case Reports
P-053
Contrast enhanced ultrasound in carotid atherosclerosis
T. Balakhonova (Russia)
P-054
Experience in the use of statins in patients with chronic myocarditis and heart failure with
preserved ejection fraction
S. Grishaev (Russia)
Epidemiology
P-055
State carotid arteries and lipid metabolism in healthy women in different periods of life
Y. Brytkova (Russia)
P-056
Risk factors of CVD and the necessity for population-based prevention in Tomsk
E. Efimova (Russia)
P-057
Prehypertension prevalence in population-based sample of Saint-Petersburg inhabitants
A. Erina (Russia)
P-058
Peculiarities of Coronary Arteries Lesion in CHD patients in Donetsk region (Ukraine)
I. Mykhailichenko (Ukraine)
P-059
Concordance of Glucose Based and of HbA1c Based Diagnoses of Diabetes in Patients With
Established Coronary Atherosclerosis: A Comparison Between Men And Women
A. Leiherer (Austria)
P-060
12-year dynamics of blood lipid parameters in in ageing population in Russia
K. Makarenkova (Russia)
P-061
Metabolic profile of female survivors of Siege of Leningrad
E. Moguchaia (Russia)
P-062
Lipid ratios and ambulatory blood pressure: implication of HDL-C, expectations, and
concerns
E. Pello (Russia)
P-063
Left ventricular diastolic dysfunction, the traditional risk factors in women with systemic
lupus erythematosus
M. Sokhova (Russia)
P-064
Prevalence of hidden diabetes in our population with risk factors by ambulatory glycated
hemoglobin determination
M. Villaescusa (Spain)
Genetics
P-065
Polymorphism Аrg389Gly gene ADRB1 in patients with chronic heart failure of Uzbek
nationality
U. Kamilova (Uzbekistan)
P-066
The role of composite of platelet receptors genes and cytochrome P450 genes
polymorphisms in developing of adverse cardiovascular events in patients with
atherosclerosis and coronary heart disease
A. Kosinova (Russia)
P-067
HDL prevent apoptosis of human primary macrophages and THP-1 macrophages through
stimulation of FOXO1 phosphorylation
E. Larionova (Russia)
P-068
Quercetin Counteracts Hypoxia-Mediated Modulation of Gene Expression in SGBS
Adipocytes
A. Leiherer (Austria)
P-069
Association TRPA1, TRPV1 genes with myocardial infarction in Siberia Caucasians
P. Orlov (Russia)
P-070
Genetic markers of cardiovascular disease determined by seven SNPs identified in genomewide association studies in Arctic Circle (Yakutia study)
A. Romanova (Russia)
P-071
Sterol regulatory element binding transcription factor 2 gene rs2228314 single nucleotide
polymorphism and lipid profile in Caucasian population of west Siberia
E. Shakhtshneider (Russia)
P-072
Influence of distribution of lipidtransport system genes polymorphism on level of a coronary
atherosclerosis at patients with unstable angina
A. Shek (Uzbekistan)
P-073
Pathogenetic role of Notch signaling in calcific aortic valve stenosis
A. Shishkova (Russia)
Varia
P-075
Impact of Individual Acute Phase Serum Amyloid A Isoforms on HDL Metabolism in Mice
M. De Beer (United States)
P-076
Hypoxia-induced immune organs and cells response in experiment background infection
A. Isayev (Azerbaijan)
P-077
Complicated course of atherosclerosis and hemodynamic disturbances in reconstructive
surgery of vessels
M. Khvostova (Russia)
P-078
A comparative study of the influence of psychogenic trauma on lipid metabolism in male and
female rats
N. Klyueva (Russia)
P-079
Vegetative regulation in patients with chronic obstructive pulmonary disease in combination
with obstructive sleep apnea syndrome
M. Koshkina (Russia)
P-080
Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic
aneurysm
A. Kostina (Italy)
P-082
Influence of cardiorehabilitation on clinical outcomes, physical performance, blood lipids in
patients after endovascular intervention in the long-term period
I. Matveeva (Russia)
P-083
LDL aggregation inhibitors do not reduce their atherogenic potential
A. Melnichenko (Russia)
P-084
Comparative assessment of different methods of vascular allografts recellularization
efficiency
A. Mishanin (Russia)
P-085
Does physical activity influence the development of atherosclerotic process?
M. Ermina (Russia)
P-086
Arginine residues of proteins and their role in binding of cholesterol
N. Nikulcheva (Russia)
P-087
Hypercholesterolemia as heart failure morphological remodeling major factor (experimental
atherosclerosis model)
K. Nona (Georgia)
P-088
One century of cholesterol atherosclerosis model creation
N. Parfenova (Russia)
P-089
Atherosclerosis and antiphospholipid syndrome
N. Seredavkina (Russia)
P-090
Pregnancy and lipid status in view of heredity, burdened by early cardiovascular disease
O. Sergeeva (Russia)
P-091
Binding of Lewis Y to Leukocyte Thrombomodulin Mediates Leukocyte Adhesion via
Activation of p38 MAPK and β2-integrins
H.-L. Wu (Taiwan)
Friday, June 3, 2016
Cardiology/Hypertension
P-016
Importance of evaluation and quantificantion of left atrial function using strain imaging
J. Claessens (Belgium)
P-017
Non-invasive contribution to the diagnosis of ischemic heart disease using Speckle-Tracking
Echocardiography of the left ventricle
J. Claessens (Belgium)
Biomarkers
P-092
Arterial stiffness detected by different methods in population-based sample of SaintPetersburg inhabitants
A. Alieva (Russia)
P-093
PCSK9 level in male population and its association with atherosclerosis risk factors
K. Astrakova (Russia)
P-094
Markers of myocardial necrosis and acid-base balance parameters after beating-heart
coronary bypass grafting in type two diabetes patients
S. Borodashkina (Russia)
P-095
Postprandial hyperlipidemia correlates with a degree of coronary atherosclerosis
M. Bubnova (Russia)
P-096
Paraoxonase-1 overexpression prevents experimental abdominal aortic aneurysm
progression
E. Burillo (Spain)
P-097
Inflammation enhances mortality in patients on renal replacement therapy
M. Çafka (Albania)
P-098
Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet
activation in patients with acute coronary syndrome, with and without ongoing low-dose
aspirin treatment
G. Davì (Italy)
P-099
Endothelial dysfunction markers in liver and kidney transplant recipients
E. Grigorenko (Belarus)
P-100
Apolipoprotein B versus non-high-density lipoprotein cholesterol: Association with markers
of endothelial dysfunction and subclinical atherosclerosis
D. Karasek (Czech Republic)
P-101
The relationship of FGF-21 and A-FABP to markers of insulin resistance and endothelial
dysfunction in individuals with dyslipidemia
D. Karasek (Czech Republic)
P-102
Age and gender properties of protein growth factors and damages in acute coronary
syndromes
G. Kayumova (Russia)
P-103
Clinical significance of the protein growth factors and injury in acute coronary syndrome
G. Kayumova (Russia)
P-104
Hypercortisolaemia as a biomarker of long-term prognosis in patients with myocardial
infarction
K. Kholmatova (Russia)
P-105
Investigating the underlying mechanisms in high risk CAD by studying patient specific iPSCs
derived hepatocyte models in vitro
M. Kiamehr (Finland)
P-106
Inflammation markers and lipid profile analysis in the patients after myocardial
revascularization
K. Korzhenevskaia (Russia)
P-107
Evaluation of Uromodulin as new serum marker for renal function and the incidence of
chronic kidney disease
A. Leiherer (Austria)
P-108
Markers of vascular inflammation in patients with coronary artery disease and arterial
hypertension
T. Petelina (Russia)
P-109
Tissue RAS activity in hypertensive patients with atherosclerosis
I. Mykhailichenko (Ukraine)
P-110
Simvastatin and omega-3 polyunsaturated fatty acid in connective tissue dismetabolism
correction in the cerebral vessels in experimental tobacco model
V. Nevzorova (Russia)
P-111
Lipoprotein-associated phospholipase A2 and carotid atherosclerosis in patients with
coronary heart disease and hypoalphalipoproteinemia
G. Osmankulova (Kyrgyzstan)
P-112
Relationship between risk factors and parameters of the lipid profile and markers of the
inflammatory response in patients with hemodynamically significant coronary artery disease
T. Petelina (Russia)
P-113
sApo-1/Fas and sBcl-2 as markers of apoptosis in acute coronary syndrome
N. Petrishchev (Russia)
P-114
Levels of osteocalcin, osteoprotegerin and calcitonin in atherosclerotic plaques of the
coronary arteries
Y. Polonskaya (Russia)
P-115
Role of interleukin-18 in estimation of hospital complications in subjects with coronary artery
disease who underwent coronary artery bypass grafting
K. Shafranskaya (Russia)
P-116
Significant biochemistry lipid and non-lipid biomarkers of coronary atherosclerosis in Siberia
V. Shramko (Russia)
P-117
Features of the cytokine profile, ST2 level and markers of endothelial dysfunction in patients
with acute myocardial infarction and different methods of myocardial revascularization
L. Slatova (Russia)
P-118
Association of matrixmetalloproteinase-9, pentraxin-3 and galectin-3 with risk for
cardiovascular disease development in chronic renal disease patients
A. Stefanović (Serbia)
P-119
Nutritional, inflammation and oxidative stress parameters: Mortality risk in hemodialysis
patients
M. Stojanov (Serbia)
Familial hypercholesterolemia
P-121
Mutational analysis of PCSK9 gene in a group of patients with familial hypercholesterolemia
– the Polish National Centre of Diagnostics and Treatment of Familial Hypercholesterolemia
report
M. Chmara (Poland)
P-122
Targeted next-generation sequencing of the APOB gene in patients with familial
hypercholesterolemia
D. Ivanoshchuk (Russia)
P-123
Lipid profile influence on epicardial fat thickness in familial hypercholesterolemia patients
V. Korneva (Russia)
P-124
Problem Statement and Perspectives in Early Identification of Patients with Familial
Hypercholesterolemia in the Kyrgyz Republic
A. Okunova (Kyrgyzstan)
P-125
The First Experience in Monitoring Patients with Familial Hypercholesterolemia in the Kyrgyz
Republic
A. Okunova (Kyrgyzstan)
P-126
FH homozygote without cardiovascular disease at the age of 40
L. Schwarzova (Czech Republic)
P-127
Frequency of familial hypercholesterolaemia among adults with severe
hypercholesterolaemia
S. Urazgildeeva (Russia)
Metabolic Syndrome (Diabetes, Obesity)
P-128
Carotid arteries subclinical damage in patients with abdominal obesity
E. Baranova (Russia)
P-129
Chicken Hydrolysate Diets Reduce Inflammation and Atherosclerosis Progression in High-Fat
Fed Mice
R. Berge (Norway)
P-130
TWEAK blockade decreases atherosclerotic lesion size and progression through
suppression of STAT signaling in diabetic mice
L. Blanco-Colio (Spain)
P-131
The distribution of the metabolic disorders among obese patients, depending on the
metabolic status
M. Boyarinova (Russia)
P-132
C-reactive protein and high molecular weight adiponectin in women with abdominal obesity:
carotid intimal media thickness of common carotid arteries
D. Brovin (Russia)
P-133
Some aspects of left ventricular remodeling in hypertensive patients with diabetic
nephropathy
N. Demikhova (Ukraine)
P-134
Pathogenetic interrelationships of atherosclerosis and type 2 diabetes
P. Bondarenko (Russia)
P-135
Telmisartan attenuates hyperglycemia-aggravated VCAM-1 expression and monocytes
adhesion in TNFα-stimulated endothelial cells by increasing GSK3β-Ser9 phosphorylation
D.-H. Cho (Korea)
P-136
Effects of insulin resistance at lipid profile in hypertensive patients with normal and
overweight
E. Ievskaia (Russia)
P-137
Significance of the body weight in endothelial dysfunction changes and systemic
inflammation progression in coronary artery disease patients
I. Ilchenko (Ukraine)
P-138
Role of profibrogenic factors in increasing of arterial stiffness in patients with metabolic
syndrome
V. Ionin (Russia)
P-139
Galvus the correction of dyslipidemia in patients with type 2 diabetes and metabolic
syndrome
G. Ismayilova (Azerbaijan)
P-141
The association between obesity, adipokines levels and inflammation in patients with early
rheumatoid arthritis
L. Kondratyeva (Russia)
P-142
Beneficial Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery
Disease in Patients with Diabetes
D.-H. Lee (Korea)
P-143
High Triglycerides, Low HDL Cholesterol and a Low LDL Cholesterol per Apolipoprotein B
Ratio Predict Incident Diabetes in Patients with Established Coronary Artery Disease
A. Leiherer (Austria)
P-144
Remnant Cholesterol Predicts Cardiovascular Event Risk in Patients With Type 2 Diabetes
Independently From The Baseline Coronary Artery Disease State
A. Leiherer (Austria)
P-145
Simvastatin influence on left ventricle diastolic function and endothelial function at patients
with metabolic syndrome features
D. Mailian (Ukraine)
P-146
Subclinical atherosclerosis in patients with psoriatic arthritis: its relationship with metabolic
syndrome and disease activity
E. Markelova (Russia)
P-147
N-acetyltransferase 2/NAT2 – regulator of lipid homeostasis: New/old player in metabolism of
patients with ischaemic heart disease and metabolic syndrome
S. Matveeva (Russia)
P-148
Dyslipidemia and type II diabetes mellitus risk
S. Mustafina (Russia)
P-149
Epicardial adipose tissue thickness in patients with arterial hypertension and relation with
metabolic parameters associated with cardiovascular risk
O. Nilova (Russia)
P-150
The clinical features of acute coronary syndrome in patients with diabetes mellitus subjected
to PCI during hospitalization
O. Stoiko (Russia)
P-151
A case of reversible diastolic dysfunction in patients with diabetes mellitus
D. Orlov (Russia)
P-152
Features lipid profile in obesity, pre-diabetes and newly diagnosed type 2 diabetes
G. Petrik (Russia)
P-153
Role of atherogenetic, metabolic, and psychic factors in patients with colorectal adenomas
L. Roncucci (Italy)
P-154
Occurrence of overweight and obesity among doctors and nurses
G. Shavkuta (Russia)
P-155
Insulin Downregulates Apolipoprotein A-I Gene Expression in Human Hepatoma Cell Line
HepG2
V. Shavva (Russia)
P-156
Neuroprotective effect of liraglutide in patients with metabolic syndrome
A. Simanenkova (Russia)
P-157
The indices of lipid and carbohydrate metabolism and local fat depot in patients with
metabolic syndrome
A. Solovjeva (Russia)
P-159
Physiological changes of adipokines during the menstrual cycle
M. Šrámková (Czech Republic)
P-160
Adiponectin modulates apolipoprotein production in THP-1 macrophages
D. Tanyanskiy (Russia)
P-161
Efficacy and safety of fenofibrate in the treatment of dyslipidemia in patians with metabolic
syndrome associated with nonalcoholic fatty liver disease
N. Tkacheva (Russia)
P-162
Lipoprotein (a) in dyslipidemic subjects: Association with haemostatic markers of endothelial
dysfunction, markers of insulin resistance, metabolic syndrome, and IMT
H. Vaverkova (Czech Republic)
P-163
The role of individual triglycerides in the pathology of coronary artery disease
A. Yakimenko (Russia)
P-164
Gene variants determine parametrs of metabolic syndrom in children after intensive regime
change
L. Zlatohlavek (Czech Republic)
Pharmacol treatment of HLP
P-166
Studying the effectiveness of Omacor on lipid metabolism in patients with chronic heart
failure
U. Kamilova (Uzbekistan)
P-167
Effects of Fimasartan on Carotid Atherosclerosis Progression after Mechanical Injury in
ApoE Knockout Mouse
J.-H. Kim (Korea)
P-170
The role of Omacor treatment in morphological changes of venous grafts in patients after
surgical myocardial revascularisation
K. Korzhenevskaia (Russia)
P-171
Compliance to statins and antiaggregants therapy in patients 5 years ago suffered of acute
coronary syndrome (experience of regional cardiovascular centre)
V. Kostenko (Russia)
P-172
The effects of atorvastatin treatment on the mean platelet volume and red cell distribution
width in patients with dyslipoproteinemia and comparison with plasma atherogenicity
indicators – A pilot study
P. Kruzliak (Czech Republic)
P-173
Inhibition of mevalonate diphosphate decarboxylase in the cholesterol biosynthesis pathway
causes replication stress
M. A. Lasunción (Spain)
P-174
Assessment of the quality of lipid-lowering therapy according to outpatient registry data
S. Martsevich (Russia)
P-175
Improvement of lipid-lowering therapy efficacy and tolerability in patients at high
cardiovascular risk and concomitant liver disease with ursodeoxycholic acid
S. Martsevich (Russia)
P-176
Comparative study of atorvastatin and simvastatin efficacy in patients with ischemic heart
disease
D. Masharipova (Uzbekistan)
P-177
New lipid-lowering property of the active drug Hypoxen (experimental study)
I. Okunevich (Russia)
P-178
Adherence to prescribed therapy and its influence on the serum lipid levels аmong patients
with coronary artery disease
Y. Orekhova (Russia)
P-179
Results of simvastatin applying in the patients of senile age with CHD
A. Pirogov (Russia)
P-180
Pitavastatin Lowers Plasma Levels of Coq10 less than Equipotent Doses of Rosuvastatin or
Atorvastatin
P. Moriarty (United States)
P-181
Peculiarities of risk stratification for patients with unstable angina pectoris and type 2
diabetes mellitus
R. Trigulova (Uzbekistan)
P-182
Assessment of dynamics of carotid atherosclerosis on short-term intensive statins therapy:
the plaques volume versus the intima-media thickness
M. Tripoten (Russia)
P-183
Specifics of the blood serum triglycerides composition in men with CAD treated with
simvastatin
A. Yakimenko (Russia)
Last update on May 23, 2016.